美国急性闭角型危象的流行病学、散瞳安全性及药物相关风险
该回顾性队列研究基于美国多中心电子健康记录网络,评估2010至2025年急性闭角型危象(AACC)的流行病学、药物性散瞳的安全性及药物相关AACC风险。研究发现散瞳后AACC罕见(每10万次散瞳检查3.1例),主要发生于解剖易感患者;多种药物与AACC风险升高相关,包括钙通道阻滞剂、CGRP单抗和PCSK9抑制剂等新报告关联。
要点
- 药物性散瞳后AACC罕见,支持常规散瞳安全性。
- AACC发病率和PACG患病率随时间上升,房角镜检查使用下降。
- 多种药物与AACC风险升高相关,需主动评估眼部风险。
核心结论
- 药物性散瞳后AACC罕见,主要发生于解剖易感患者,支持常规散瞳安全性。
- 药物相关AACC风险信号强调主动眼部风险评估和药物核查的重要性。
- 钙通道阻滞剂、CGRP单抗和PCSK9抑制剂的新关联需进一步研究。
研究设计与样本
- 回顾性临床队列研究,使用2010至2025年多中心联邦电子健康记录网络去标识化数据。
- 研究对象为≥18岁成人,AACC病例通过ICD-10-CM编码及14天内确定性治疗干预识别。
- 散瞳相关AACC风险在散瞳眼科检查患者中评估,14天内新发AACC(含24小时敏感性分析)。
- 药物相关AACC风险采用活性对照队列,1:1倾向评分匹配,30天窗口Cox比例风险模型。
主要发现
- 2010至2025年AACC累积发病率为0.014%,AACC患者中原发性闭角型青光眼(PACG)患病率为16.7%。
- AACC发病率和AACC患者中PACG患病率随时间增加(均P < .001)。
- 房角镜检查使用下降,而前节成像增加(均P < .001)。
- 在2,444,570例患者的3,400,372次散瞳检查中,散瞳后AACC罕见(每10万次3.1例;95% CI: 2.3-3.7),24小时敏感性分析结果相似,事件集中于有解剖危险因素的患者。
关键数值与推荐
- AACC累积发病率0.014%,AACC患者中PACG患病率16.7%。
- 散瞳后AACC发生率每10万次检查3.1例(95% CI: 2.3-3.7)。
- 乳酸果糖HR 1.67、甲氧氯普胺HR 1.38、舒马曲普坦HR 1.64、哌唑嗪HR 1.32、特拉唑嗪HR 1.77(均P < .05)。
- 依瑞奴单抗HR 1.33、维拉帕米HR 1.89、地尔硫䓬HR 1.74、阿利西尤单抗HR 1.54、依洛尤单抗HR 1.46(均P < .05)。
临床怎么用
- 常规药物性散瞳在解剖易感患者中AACC风险低,可支持临床散瞳实践。
- 对使用钙通道阻滞剂、CGRP单抗、PCSK9抑制剂等药物的患者应主动评估眼部风险并核查用药。
- 房角镜检查使用下降而前节成像增加,需关注对闭角型青光眼评估的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the epidemiology of acute angle-closure crisis (AACC), the safety of pharmacologic dilation, and medication-associated AACC risk in the United States. DESIGN: Retrospective clinical cohort study. SUBJECTS: Adults (≥18 years) in a multicenter federated electronic health record network. METHODS: Using deidentified electronic medical record data from 2010 to 2025, AACC cases were identified using ICD-10-CM codes followed by definitive therapeutic intervention within 14 days. Incidence, prevalence, and diagnostic trends were evaluated with Mann-Kendall tests. Dilation-associated AACC risk was assessed among patients undergoing dilation-associated ophthalmic examinations, with incident AACC identified within 14 days (with 24-hour sensitivity analysis). Medication-associated AACC risk was evaluated using active-comparator cohorts with 1:1 propensity score matching and Cox proportional hazards models over a 30-day window. MAIN OUTCOME MEASURES: AACC incidence (per 100,000 dilation-associated examinations) and hazard ratios (HRs) with 95% confidence intervals (CIs) for medication-associated AACC risk. RESULTS: From 2010 to 2025, the cumulative incidence of AACC was 0.014%, and the prevalence of primary angle-closure glaucoma (PACG) among patients with AACC was 16.7%. AACC incidence and the prevalence of PACG among patients with AACC increased over time (all P < .001). Gonioscopy utilization declined, whereas anterior segment imaging increased (all P < .001). Across 3,400,372 dilation-associated examinations among 2,444,570 patients, post-dilation AACC was rare (3.1 per 100,000; 95% CI: 2.3-3.7), with similar findings in a 24-hour sensitivity analysis; events concentrated among patients with anatomical risk factors. Increased AACC risk was observed for medications with established associations and some with less established associations, including lactulose (HR: 1.67), metoclopramide (1.38), sumatriptan (1.64), prazosin (1.32), and terazosin (1.77) (all P < .05). Previously unreported associations were observed for calcitonin gene-related peptide (CGRP) monoclonal antibodies (erenumab [1.33]), calcium channel blockers (CCBs) (verapamil [1.89], diltiazem [1.74]), and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab [1.54], evolocumab [1.46]) (all P < .05). CONCLUSIONS: AACC following pharmacologic dilation was rare and occurred predominantly among anatomically predisposed patients, supporting the safety of dilation in routine care. Medication-associated risk signals highlight the importance of proactive ocular risk assessment and medication reconciliation. Novel associations with CCBs, CGRP monoclonal antibodies, and PCSK9 inhibitors warrant further investigation.
引用
- Shah J, Pathuri S, Adamovich-Zeitlin R, et al. Epidemiology, Safety of Dilation, and Medication-Associated Risk of Acute Angle-Closure Crisis in the United States. Am J Ophthalmol. 2026. PMID: 42431436. doi:10.1016/j.ajo.2026.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。